Search

Search Results

• TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.

  Charicleia Kelaidi, Lionel Ades, Pierre Fenaux

  e2011038

  2011-09-08

  https://doi.org/10.4084/mjhid.2011.038

  2388

  PDF: 907

  HTML: 2315

• TREATMENT OF ADOLESCENT AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

  Josep-Maria Ribera, Jordi Ribera, Eulàlia Genescà

  e2014052

  2014-07-02

  https://doi.org/10.4084/mjhid.2014.052

  2536

  PDF: 1275

  HTML: 5886

• PATHOBIOLOGY AND TREATMENT OF HEPATITIS VIRUS-RELATED THROMBOCYTOPENIA

  Roberto Stasi, Lian Wea Chia, Pallavi Kalkur, Robert Lown, Muriel S. Shannon

  e2009023

  https://doi.org/10.4084/mjhid.2009.023

  817

  PDF: 576

  HTML: 1435

• Immune thrombocytopenic purpura cases following COVID-19 vaccination.

  Annalisa Condorelli, Uros Markovic, Roberta Sciortino, Mary Ann Di Giorgio, Daniela Nicolosi, Gaetano Giuffrida

  e2021047

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.047

  1065

  PDF: 385

  HTML: 295

• LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

  Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena

  e2011021

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.021

  1536

  PDF: 766

  HTML: 839

  jdoe, table 2 infections CML .doc: 174

  jdoe, table 1 infections CML .doc: 160

• Early use of thrombopoietin receptor agonists (Tpo-Ras) in clinical practice: results from an Italian survey on behalf of the GIMEMA Working Group Anemia and Thrombocytopenia

  Mariasanta Napolitano, elisa lucchini, maria rosaria de paolis, antonio urso, nicola vianelli, francesco zaja, cristina santoro

  e2025041

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.041

  821

  PDF: 624

  HTML: 132

• PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID

  Francesco Rodeghiero

  e2021032

  2021-04-29

  https://doi.org/10.4084/MJHID.2021.032

  2296

  PDF: 884

  HTML: 482

• ATYPICAL DIFFERENTIATION SYNDROME WITH SUDDEN VISION LOSS IN ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ATRA PLUS ATO: A CLINICAL CASE

  Eleonora Boscaro

  e2024063

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.063

  894

  PDF: 875

  HTML: 96

• A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fabrizio Pane

  e2014010

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.010

  3155

  PDF: 1299

  HTML: 4104

• THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone

  George J Kontoghiorghes, Marios Kleanthous, Christina N. Kontoghiorghe

  e2020011

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.011

  2249

  PDF: 1539

  HTML: 577

• Isavuconazole therapy of disseminated and encephalic Saprochaete capitata infection in an acute myeloid leukemia patient treated with midostaurin.

  Salvatore Perrone, Chiara Lisi, Elettra Ortu La Barbera, Cristina Luise, Miriam Lichtner, Corrado Girmenia, Giuseppe Cimino

  e2020026

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.026

  1333

  PDF: 768

  HTML: 297

• Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy

  Pasquale Niscola

  e2013030

  2013-04-16

  https://doi.org/10.4084/mjhid.2013.030

  1133

  PDF: 721

  HTML: 1330

  Figure 1: 157

  Figure 2: 155

• DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA

  Ali Taher

  e2018066

  2018-11-01

  https://doi.org/10.4084/mjhid.2018.066

  2756

  PDF: 1536

  HTML: 216

• INFECTIONS IN THALASSEMIA AND HEMOGLOBINOPATHIES

  Bianca Maria Ricerca, Arturo Di Girolamo, Deborah Rund

  e2009028

  2009-12-28

  1040

  PDF: 591

  HTML: 4264

• ACQUIRED HYPOGONADOTROPIC HYPOGONADISM (AHH) IN THALASSAEMIA MAJOR PATIENTS: AN UNDERDIAGNOSED CONDITION?

  Vincenzo De Sanctis

  e2016001

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.001

  5038

  PDF: 1253

  HTML: 3547

• Nodular lymphocyte-predominant Hodgkin lymphoma in a patient with Familial Mediterranean Fever

  Marina Belia, Asimina Papanikolaou, Panagiotis Skendros, Theodoros Vassilakopoulos

  e2022059

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.059

  915

  PDF: 470

  HTML: 256

• LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE

  Patrizia Tosi

  e2013037

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.037

  1217

  PDF: 866

  HTML: 1243

  fig 1A: 153

  figure1B: 127

• Severe autoimmune hemolytic anemia in Covid-19 infection Autoimmune hemolytic anemia in Covid-19

  Fehmi Hindilerden, Ipek Yonal-Hindilerden, Emre Akar, Zuhal Yesilbag, Kadriye Kart-Yasar

  e2020053

  2020-09-14

  https://doi.org/10.4084/mjhid.2020.053

  3032

  PDF: 1527

  HTML: 248

• EVALUATION OF ORAL DOXYCYCLINE, AZITHROMYCIN, OR SEQUENTIAL DOXYCYCLINE-AZITHROMYCIN TREATMENT FOR SCRUB TYPHUS-

  Hanchen Liu, Weizhen Wang, Yuqing Dong

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.020

  533

  PDF: 304

  HTML: 70

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  1950

  PDF: 776

  HTML: 195

• ACUTE LEUKEMIA AND LATENT TUBERCULOSIS INFECTION IN ITALY: QUANTIFERON-TB TEST SCREENING IN A LOW TUBERCULOSIS INCIDENCE COUNTRY

  Andrea Nunzi, Luigi Della Valle, Elisa Linnea Lindfors Rossi, Giorgia Ranucci, Flavia Mallegni, Federico Moretti, Elisa Meddi, Luca Guarnera, Ilaria Tiravanti, Kristian Taka, Elisa Buzzatti, Fabiana Esposito, Roberto Secchi, Francesca Di Giuliano, Flavia Chirico, Raffaele Palmieri, Luca Maurillo, Francesco Buccisano, Carmelo Gurnari, Giovangiacinto Paterno, Adriano Venditti, Maria Ilaria Del Principe

  e2024054

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.054

  948

  PDF: 805

  HTML: 80

• ORAL IRON-HYDROXIDE POLYMALTOSE COMPLEX VERSUS SUCROSOMIAL IRON FOR CHILDREN WITH IRON DEFICIENCY WITH OR WITHOUT ANEMIA: A CLINICAL TRIAL WITH EMPHASIS ON INTESTINAL INFLAMMATION

  Miss Sonia Alexiadou, Mrs. Christina Tsigalou, Mrs. Eleni Kourkouni, Professor Aggelos Tsalkidis, Professor Elpis Mantadakis

  e2024075

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.075

  1515

  PDF: 738

  HTML: 466

• CLINICAL MANIFESTATIONS, IMAGING FEATURES, AND TREATMENT FOLLOW-UP OF 29 CASES WITH HEPATIC TUBERCULOSIS

  Saiduo; Wei, Jichan, Xinchun, Hongye, Ning, Xiangao Jiang

  e2022063

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.063

  790

  PDF: 715

  HTML: 391

• PROPHYLACTIC ADMINISTRATION OF DOXYCYCLINE REDUCES CENTRAL VENOUS CATHETER INFECTIONS IN PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION

  Mohamed Kharfan-Dabaja, Mohamed Baydoun, Zaher Otrock, Samar Okaily, Rita Nehme, Racha Abu-Chahine, Ali Hamdan, Samar Noureddine, Souha Kanj, Zeina Kanafani, Ali Bazarbachi

  e2013015

  2013-02-16

  https://doi.org/10.4084/mjhid.2013.015

  1457

  PDF: 831

  HTML: 1369

• PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

  Giuseppe G.M. Leone, Ugo Testa

  e2025080

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.080

  858

  PDF: 288

  Html: 67

• BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.

  Roberto Castelli

  e2016030

  2016-07-01

  https://doi.org/10.4084/mjhid.2016.030

  4251

  PDF: 948

  HTML: 1642

• JADENU® SUBSTITUTING EXJADE® IN IRON OVERLOADED ?- THALASSEMIA MAJOR (BTM) PATIENTS: A PRELIMINARY REPORT OF THE EFFECTS ON THE TOLERABILITY, SERUM FERRITIN LEVEL, LIVER IRON CONCENTRATION AND BIOCHEMICAL PROFILES

  Vincenzo De Sanctis

  e2018064

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.064

  2515

  PDF: 1178

  HTML: 228

• SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib

  Matteo Molica

  e2024079

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.079

  898

  PDF: 485

  HTML: 171

• HEMATOPOIETIC STEM CELL TRANSPLANTATION IN EGYPT CHALLENGES AND OPPORTUNITIES

  Hossam Kamel Mahmoud, Gamaleldin Mohamed Fathy, Alaa Elhaddad, Omar Abdelrahman Fahmy, Mohamed Abdelmooti, Raafat Abdelfattah, Mahmoud Tarek Sayed Ahmed Bokhary

  e2020023

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.023

  1742

  PDF: 945

  HTML: 583

• LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML

  Xavier Thomas, Marica Laurino, sandrine loron, marie-virginie larcher, gaëlle fossard, mohamed elhamri, alexandre deloire, marie balsat, fiorenza barraco, hélène labussière, sophie ducastelle, myriam renault, eric wattel, maël heiblig, gilles salles

  e2020020

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.020

  1599

  PDF: 1124

  HTML: 229

• CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment

  Michele Malagola, Raffaella Greco, Stella Santarone, Anna Paola Iori, Luisa Quatrocchi, Walter Barberi, Bruzzese Antonella, Salvatore Leotta, Alessandra Carotti, Antonio Pierini, Simon Bernardi, Enrico Morello, Nicola Polverelli, Alessandro Turra, Federica Cattina, Lisa Gandolfi, Benedetta Rambaldi, Francesca Lorentino, Francesca Serio, Annalisa Natale, Giuseppe Milone, Andrea Velardi, Robin Foà, Fabio Ciceri, Domenico Russo, Jacopo Peccatori

  e2019048

  2019-08-29

  https://doi.org/10.4084/mjhid.2019.048

  1855

  PDF: 1124

  HTML: 248

• Impact of hydroxyurea on clinical and biological parameters of sickle cell anemia in children in Abidjan

  MIREILLE YAYO- AYE, Adia Eusèbe Adjambri, Boidy Kouakou, Rebecca N'guessan-Blao, Louis Missa Adjé, Taïratou Kamagaté, Vincent Yapo, Duni Sawadogo

  e2024026

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.026

  678

  PDF: 1071

  HTML: 62

• Late-Onset Veno-Occlusive Disease (VOD) Post-Haploidentical Transplant: A Diagnostic Challenge Requiring Liver Biopsy– A Case Report

  Mehak Trehan, Homdutt Sharma, Abhinav Sengupta, Anirudh Burli, Pradeep Kumar, Manoranjan Mahapatra

  e2025068

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.068

  858

  PDF: 404

  Html: 120

• EPIDEMIOLOGY OF ACTIVATED PROTEIN C RESISTANCE AND FACTOR V LEIDEN MUTATION IN THE MEDITERRANEAN REGION

  Mehrez Mehrez M. Jadaon

  e2011037

  2011-09-08

  https://doi.org/10.4084/mjhid.2011.037

  3062

  PDF: 767

  HTML: 12876

• SAFETY OF BRONCHOALVEOLAR LAVAGE IN HEMATOLOGICAL PATIENTS WITH THROMBOCYTOPENIA – A RETROSPECTIVE COHORT STUDY

  Ivan GUR, Roei Tounek, Yaniv Dotan, Elite Vainer Evgrafov, Stav Rakedzon, Eyal Fuchs

  e2024006

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.006

  1060

  PDF: 1259

  HTML: 161

• Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review

  Domenico Santorsola, Elisabetta Abruzzese

  e2015020

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.020

  1950

  PDF: 1173

  HTML: 1611

• Evaluation of VTE-PREDICT risk score in patients receiving low-dose DOACs for venous thromboembolism (VTE) secondary prophylaxis

  Alessandro Laganà, Giovanni Manfredi Assanto, Mauro Passucci, Cristina Santoro, Antonio Chistolini

  e2024047

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.047

  1107

  PDF: 952

  HTML: 73

• EFFICACY AND SAFETY OF CLADRIBINE: SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN HAIRY CELL LEUKEMIA PATIENTS

  Ola Khorshid, Safaa M. Ramadan

  e2015058

  2015-10-16

  https://doi.org/10.4084/mjhid.2015.058

  1943

  PDF: 1029

  HTML: 1182

• TYROSINE KINASE INHIBITORS AND PREGNANCY

  Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti

  e2014028

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.028

  3427

  PDF: 1579

  HTML: 2662

• Luspatercept Treatment in a β-Thalassemia Patient with Pulmonary Arterial Hypertension: A Case Report

  beibei yang, dongmei liu, changyu yang, Yali zhou, Guiping Liao, jian huang, Yingying Li, yinjiang tang, xiaolin yin

  e2025059

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.059

  944

  PDF: 504

  Html: 129

• OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES

  Jon Salmanton-Garcia, Francesco Marchesi, Oliver A. Cornely, Jannik Stemler, Pierantonio Menna

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.022

  766

  PDF: 899

  Suppl. Files: 112

  HTML: 62

• NEW STRATEGIES FOR STEM CELL MOBILIZATION

  Roberto Lemoli

  e2012066

  2012-10-03

  https://doi.org/10.4084/mjhid.2012.066

  2325

  PDF: 822

  HTML: 2440

• CURRENT STRATEGIES FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

  Juliana Maria Camargos Rocha, Sandra Guerra Xavier, Marcelo Eduardo Lima Souza, Juliana Godoy Assumpção, Mitiko Murao, Benigna Maria Oliveira

  e2016024

  2016-04-10

  https://doi.org/10.4084/mjhid.2016.024

  4459

  PDF: 1293

  HTML: 4590

• Multiple bone and joint disease in a sickle cell anaemia patient: a case report

  John Ayodele Olaniyi, Adekunle E Alagbe, Olutoogun O Toluwalase, Olorunsogo E Busari

  e2012023

  2012-05-03

  https://doi.org/10.4084/mjhid.2012.023

  1200

  PDF: 701

  HTML: 1696

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3618

  PDF: 1014

  HTML: 1787

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1616

  PDF: 623

  HTML: 2413

• THE ICET-A RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF DISTURBANCES OF GLUCOSE HOMEOSTASIS IN THALASSEMIA MAJOR PATIENTS

  Vincenzo De Sanctis

  e2016058

  2016-10-25

  https://doi.org/10.4084/mjhid.2016.058

  4129

  PDF: 1138

  HTML: 1157

• HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA AND SICKLE CELL DISEASE: EXPERIENCE OF MEDITERRANEAN INSTITUTE OF HEMATOLOGY IN A MULTI-ETHNIC POPULATION.

  Marco Marziali, Antonella Isgrò, Javid Gaziev, Guido Lucarelli

  e2009027

  2009-12-26

  1629

  PDF: 700

  HTML: 2901

• Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists

  Monica Carpenedo, Dr, Dr, Dr

  e2023021

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.021

  1101

  PDF: 1012

  HTML: 665

• ASSESSMENT OF THE EFFICACY OF PROCALCITONIN, C-REACTIVE PROTEIN AND ALBUMIN LEVELS-GUIDED ANTIBIOTICS USE IN SEPSIS

  Junyue Cao, YuChao Sun

  e2025060

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.060

  860

  PDF: 439

  Html: 128

  Suppl. Files: 146